Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF‑κb Expression

Oxidative stress has a prominent role in the pathogenesis of diabetes complications. Pramlintide is an injectional amylin analogue used for the treatment of type 1 and type 2 diabetic patients. The present investigation evaluated the effect of pramlintide against oxidative damage induced by hydrogen peroxide (H2 O2 ) in human umbilical vein endothelial cells (HUVECs).

Cell viability was assessed using 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide method. Hydroperoxides level, ferric reducing antioxidant power (FRAP), and expression of transcription factor NF‑κB were measured in HUVECs that pretreated with pramlintide and, then exposed to H2 O2 .

Pramlintide significantly decreased the cytotoxicity caused by H2 O2 at the concentrations of 5 and 10 µg/mL. Pretreatment of HUVECs with pramlintide reduced hydroperoxides and increased FRAP value in intra‑ and extra‑cellular mediums at different concentration ranges compared with H2 O2 stimulated cells. Pramlintide (10 µg/mL) remarkably ameliorated the expression of NF‑κB gene after 1, 3 and 24 h exposure to H2 O2 .

Findings of the current investigation displayed that pramlintide may act as a protective against oxidative conditions in endothelial cells through modulation of oxidative markers and transcription factor NF‑κB.